Advertisement

Ads Placeholder
Loading...

State Street SPDR S&P Pharmaceuticals ETF

XPH•AMEX
Financial Services
Asset Management
$54.72
$0.00(0.00%)
U.S. Market opens in NaNh NaNm

State Street SPDR S&P Pharmaceuticals ETF (XPH) Stock Overview

Explore State Street SPDR S&P Pharmaceuticals ETF’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap220.7M
P/E RatioN/A
EPS (TTM)$3.02
ROE0.00%
Fundamental Analysis

AI Price Forecasts

1 Month$48.96
3 Months$59.03
1 Year Target$60.26

XPH Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of State Street SPDR S&P Pharmaceuticals ETF (XPH) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 52.02, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $60.26.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 220.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
2.88%
1-Month Change
-1.78%
3-Month Change
-0.89%
6-Month Change
11.67%
Year-to-Date (YTD) Change
-0.89%
1-Year Change
34.48%
3-Year Change
32.53%
5-Year Change
9.09%
All-Time (Max) Change
250.54%

Contact Information

https://www.ssga.com/us/en/intermediary/etfs/funds/spdr-sp-pharmaceuticals-etf-xph?fundSeoName=spdr-sp-pharmaceuticals-etf-XPH
NaN
One Iron Street, Boston, MA, 2210

Company Facts

IPO DateJun 22, 2006
CountryUS
Actively Trading

Frequently Asked Questions